Tianzhihang (688277.SH) plans to buy 62% of Shanghai Orthopedic's shares and resume trading tomorrow

According to the Zhitong Finance App, Tianzhihang (688277.SH) announced that the company plans to purchase 62% of the shares of Shanghai Minimally Invasive Orthopedic Medical Technology Co., Ltd. (Shanghai Orthopedic) held by 5 shareholders including Suzhou Orthopedic through the issuance of shares and raise supporting capital. Trading of the company's shares will resume on July 30, 2026.

The target company is mainly engaged in R&D, production and sales of joint implant products such as knee prostheses and hip prostheses. The core subsidiary and production base are located in the United States, and have subsidiaries in Europe, Japan and other countries and regions, and has a mature overseas sales network. The target company ranks in the top ten in the world for market share in the field of joint implants. The representative product internal axle has a history of clinical application for more than 20 years, has completed more than 1 million implants worldwide, and has strong brand influence, product registration capabilities, and overseas commercialization base.

After the transaction is completed, the company will supplement the orthopedic implant product matrix, further improve the “robot+implant” integrated business layout, and accelerate the overseas launch of orthopedic surgery robot products using the target company's production and commercialization systems in the US, Europe, Japan, etc. At the same time, the target company's joint implant products are also expected to be empowered by the company's high-quality surgical robot platform to enhance product competitiveness and growth momentum. The two sides will form collaborations in product lines, channels, R&D, and clinical applications to further enhance the company's global management capabilities, industrial chain integrity, and long-term development space.